--- title: "INmune Bio (INMB) news: going concern and offering" url: "https://aibio.space/companies/inmune-bio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "INMB going concern and offering news: INmune Bio raises $4.50 million in registered direct offering with warrants. INmune Bio Inc." --- INMB INmune Bio Inc. NASDAQ · United States # INmune Bio (INMB) news INMB going concern and offering news Financings · 2026-10-29 ## [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) The offering priced at $1.50 a share, and the warrants carry a $1.65 exercise price. The auditor's report on the 2025 accounts includes a going-concern paragraph, and cash was $18.4 million at June 30, 2026. ## Latest INmune Bio news 1. 2025-06-30 Financings [INmune Bio agrees to sell 3,000,000 shares at $6.30 in $19 million direct offering](https://aibio.space/news/inmune-bio-agrees-sell-3-000-000-shares-6-30-19-million-direct/) The prospectus puts the immediate dilution to new buyers at $4.97 per share. Cash was $19,377 thousand at March 31, 2025, against an accumulated deficit of $172,843 thousand. ## INmune Bio at a glance - **Ticker**: INMB - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $18.4 million ### Related companies - [Kodiak Sciences](https://aibio.space/companies/kodiak-sciences/) NASDAQ: KOD - [Nkarta](https://aibio.space/companies/nkarta/) NASDAQ: NKTX - [Conexeu Sciences](https://aibio.space/companies/conexeu-sciences/) NASDAQ: CNXU - [Replimune Group](https://aibio.space/companies/replimune/) NASDAQ: REPL - [PepGen](https://aibio.space/companies/pepgen/) NASDAQ: PEPG - [Crescent Biopharma](https://aibio.space/companies/crescent-biopharma/) NASDAQ: CBIO - [BridgeBio Pharma](https://aibio.space/companies/bridgebio-pharma/) NASDAQ: BBIO - [Candel Therapeutics](https://aibio.space/companies/candel-therapeutics/) NASDAQ: CADL ### Also on NASDAQ - [Niagen Bioscience](https://aibio.space/companies/niagen-bioscience/) NAGE - [Adicet Bio](https://aibio.space/companies/adicet-bio/) ACET - [MoonLake Immunotherapeutics](https://aibio.space/companies/moonlake-immunotherapeutics/) MLTX - [Arcutis Biotherapeutics](https://aibio.space/companies/arcutis-biotherapeutics/) ARQT - [Cryoport](https://aibio.space/companies/cryoport/) CYRX - [Monopar Therapeutics](https://aibio.space/companies/monopar-therapeutics/) MNPR ## What INmune Bio does INmune Bio is a clinical-stage biotechnology company developing product candidates designed to reprogram the innate immune system. Its lead program, CORDStrom, is a pooled, human umbilical cord-derived mesenchymal stromal cell platform for recessive dystrophic epidermolysis bullosa (RDEB), a pediatric orphan disease with no approved systemic treatments. CORDStrom has recently completed a pivotal, blinded, randomized cross-over trial, and the company is transitioning toward regulatory submission, including a Marketing Authorization Application in the United Kingdom and the European Union and a Biologics License Application with the U.S. Food and Drug Administration. The company's other clinical-stage platforms are XPro1595, a protein therapeutic that neutralizes soluble TNF and has completed Phase I and Phase II trials in Alzheimer's Disease, and INKmune, a natural killer cell-priming platform in an open-label Phase II trial for metastatic castrate-resistant prostate cancer. The FDA granted CORDStrom Rare Pediatric Disease and Orphan Drug designations. | Product or program | What it is | Stage | |---|---|---| | CORDStrom | Pooled, human umbilical cord-derived mesenchymal stromal cells for RDEB | pivotal trial completed; transitioning toward regulatory submission | | XPro1595 | Protein therapeutic that neutralizes soluble TNF for Alzheimer's Disease | Phase I and Phase II trials completed | | INKmune | Natural killer cell-priming platform for metastatic castrate-resistant prostate cancer | open-label Phase II trial, nearing completion | Summarised from the company's [10-K filed Mar 30, 2026](https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/ea0279078-10k_inmune.htm). ## INmune Bio annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$50,000](https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/) | [$14,000](https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/) | | Research and development | [$20.7 million](https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/) | [$33.2 million](https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/) | | Net income (loss) | [-$45.9 million](https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/) | [-$42.1 million](https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/) | | Cash from operations | [-$22.6 million](https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/) | [-$33.4 million](https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/) | | Cash and equivalents | [$24.8 million](https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/) | [$20.9 million](https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $18.4 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about INmune Bio Has INmune Bio issued a going-concern warning? Our latest story on this, dated Oct 29, 2026: "INmune Bio raises $4.50 million in registered direct offering with warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/). Has INmune Bio raised money recently? Our latest story on this, dated Oct 29, 2026: "INmune Bio raises $4.50 million in registered direct offering with warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/). What is the ticker symbol of INmune Bio? INmune Bio Inc. trades under the ticker INMB on NASDAQ. Where is INmune Bio listed? INmune Bio Inc. is listed on NASDAQ. What is the SEC CIK of INmune Bio? The SEC Central Index Key (CIK) for INmune Bio Inc. is 1711754. Its filings are on SEC EDGAR. How many shares does INmune Bio have outstanding? 27,753,789 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is INmune Bio listed under? Our directory records INmune Bio Inc. under United States. What does INmune Bio do? Our directory classifies INmune Bio Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of INmune Bio? The ISIN recorded for INmune Bio Inc. is US45782T1051. Does aibio.space cover INmune Bio? aibio.space lists INmune Bio Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is INmune Bio incorporated? SEC records list its state or country of incorporation as NV. What does INmune Bio develop? INmune Bio is a clinical-stage biotechnology company developing product candidates designed to reprogram the innate immune system. Its lead program, CORDStrom, is a pooled, human umbilical cord-derived mesenchymal stromal cell platform for recessive dystrophic epidermolysis bullosa (RDEB), a pediatric orphan disease with no approved systemic treatments. What is CORDStrom from INmune Bio? CORDStrom: Pooled, human umbilical cord-derived mesenchymal stromal cells for RDEB Stage: pivotal trial completed; transitioning toward regulatory submission. What is XPro1595 from INmune Bio? XPro1595: Protein therapeutic that neutralizes soluble TNF for Alzheimer's Disease Stage: Phase I and Phase II trials completed. What was INmune Bio's revenue last year? $50,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: INmune Bio Members talk about INmune Bio (INMB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at INmune Bio, newest first. Each line links the filing it comes from. 1. 2026-10-29 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1711754/000121390026113531/ea0308597-424b5_inmune.htm) 2. 2026-09-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1711754/000121390026099700/ea030540401ex99-1.htm) 3. 2026-01-27 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1711754/000121390026008204/ea027431701ex99-1_inmune.htm) 4. 2025-12-19 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1711754/000121390025123817/ea0270011-424b5_inmune.htm) 5. 2025-12-10 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1711754/000121390025120067/ea0269071-8k_inmune.htm) 6. 2025-06-30 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1711754/000121390025059298/ea0247439-424b5_inmune.htm) 7. 2025-05-07 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1711754/000121390025040727/ea0241210-8k_inmune.htm) 8. 2025-03-07 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1711754/000121390025021719/ea0233629-424b5_inmune.htm) 9. 2025-02-10 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1711754/000121390025011733/ea023027701ex99-1_inmune.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:INMB on TradingView](https://www.tradingview.com/symbols/NASDAQ-INMB/). ## SEC filings and registration - **SEC name**: Inmune Bio, Inc. - **CIK**: 1711754 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: INMB (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 225 NE MIZNER BLVD, SUITE 640, BOCA RATON, FL, 33432 - **Phone**: 8589643720 - **Shares outstanding**: 27,753,789 as of 2026-08-06 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1711754/000121390026111207/ea0309223-8k_inmune.htm) filed 2026-10-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1711754/000121390026099700/ea0305404-8k_inmune.htm) filed 2026-09-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1711754/000121390026086135/ea0298894-10q_inmune.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1711754/000121390026083961/ea0300069-8k_inmune.htm) filed 2026-07-31 - [8-K](https://www.sec.gov/Archives/edgar/data/1711754/000121390026073983/ea0296624-8k_inmune.htm) filed 2026-07-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1711754/000121390026071082/ea0295635-8k_inmune.htm) filed 2026-06-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1711754/000121390026069611/ea0295129-8k_inmune.htm) filed 2026-06-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1711754/000121390026064144/ea0293325-8k_inmune.htm) filed 2026-06-02 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001711754), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details INmune Bio Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker INMB, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: INmune Bio Inc. - **Ticker**: INMB - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US45782T1051 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-INMB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/inmune-bio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "INmune Bio (INMB) news: going concern and offering", 2026-10-31, https://aibio.space/companies/inmune-bio/